ANNX Key Statistics, Chart & Performance
The current stock price of ANNX is 4.94 USD. In the past month the price increased by 68.75%. In the past year, price increased by 9.46%.
ANNX Latest News, Press Relases and Analysis
ANNX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.59 | 393.98B | ||
| AMGN | AMGEN INC | 14.49 | 170.62B | ||
| GILD | GILEAD SCIENCES INC | 14.55 | 147.80B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.35 | 111.68B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.5 | 73.33B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 825.75 | 55.64B | ||
| INSM | INSMED INC | N/A | 41.75B | ||
| NTRA | NATERA INC | N/A | 32.50B | ||
| BIIB | BIOGEN INC | 10.72 | 26.33B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.25 | 20.74B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.20B | ||
| INCY | INCYTE CORP | 15.06 | 18.99B |
Related stock screener links
About ANNX
Company Profile
Annexon, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, eye and brain. The company is headquartered in Brisbane California, California and currently employs 103 full-time employees. The company went IPO on 2020-07-24. The company identifies and characterizes the role of the classical complement pathway in three therapeutic areas: autoimmune, neurodegeneration and ophthalmology, using its proprietary platform. Its lead candidate, ANX005, an investigational, full-length monoclonal antibody (mAb), is formulated for intravenous administration as the potential first targeted treatment for patients with Guillain-Barre Syndrome (GBS). The company is advancing ANX1502, a novel small-molecule inhibitor of classical complement designed for oral administration in a range of chronic autoimmune diseases. The company is also advancing ANX007, designed to block C1q locally in the eye, to provide complete protection against excess classical complement activity and the loss of photoreceptor neurons.
Company Info
ANNEXON INC
1400 Sierra Point Parkway, Bldg C Suite 200
Brisbane California CALIFORNIA 94080 US
CEO: Douglas Love Esq.
Employees: 103
Phone: 16508225500
ANNEXON INC / ANNX FAQ
What does ANNX do?
Annexon, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, eye and brain. The company is headquartered in Brisbane California, California and currently employs 103 full-time employees. The company went IPO on 2020-07-24. The company identifies and characterizes the role of the classical complement pathway in three therapeutic areas: autoimmune, neurodegeneration and ophthalmology, using its proprietary platform. Its lead candidate, ANX005, an investigational, full-length monoclonal antibody (mAb), is formulated for intravenous administration as the potential first targeted treatment for patients with Guillain-Barre Syndrome (GBS). The company is advancing ANX1502, a novel small-molecule inhibitor of classical complement designed for oral administration in a range of chronic autoimmune diseases. The company is also advancing ANX007, designed to block C1q locally in the eye, to provide complete protection against excess classical complement activity and the loss of photoreceptor neurons.
Can you provide the latest stock price for ANNEXON INC?
The current stock price of ANNX is 4.94 USD. The price increased by 1.65% in the last trading session.
What is the dividend status of ANNEXON INC?
ANNX does not pay a dividend.
What is the ChartMill rating of ANNEXON INC stock?
ANNX has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Which stock exchange lists ANNX stock?
ANNX stock is listed on the Nasdaq exchange.
Can you provide the upcoming earnings date for ANNEXON INC?
ANNEXON INC (ANNX) will report earnings on 2026-03-02, after the market close.
ANNX Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to ANNX. When comparing the yearly performance of all stocks, ANNX is one of the better performing stocks in the market, outperforming 93.89% of all stocks.
ANNX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ANNX. ANNX has a great financial health rating, but its profitability evaluates not so good.
ANNX Financial Highlights
Over the last trailing twelve months ANNX reported a non-GAAP Earnings per Share(EPS) of -1.41. The EPS decreased by -34.29% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -91.34% | ||
| ROE | -129.64% | ||
| Debt/Equity | 0 |
ANNX Forecast & Estimates
14 analysts have analysed ANNX and the average price target is 14.79 USD. This implies a price increase of 199.39% is expected in the next year compared to the current price of 4.94.